Search PubMed⌕ Search

Biomedical subjects

B Simon

Publications and source records attributed to B Simon.

At least 307 records · Page 17Linked to original sources
PubMed1982

[Human acid inhibition and prevention of a drop in the transmucosal potential difference by thioprostaglandin EMD 33290].

The effect of graded doses of EMD 33290 on basal acid secretion in healthy volunteers was tested over a time period of 6 hours. In addition, studies were conducted to determine if pretreatment with this thioprostaglandin could prevent the characteristic fall in human gastric potential difference associated with intragastric instillation of 1,000 mg aspirin or of 50 ml 4 mmol/l sodium taurocholate. Basal acid output was reduced by 65% and 75% after a 2 and 3 mg single dose of EMD 33290 respectively. 1 mg of this prostaglandin E2 analog showed no detectable antisecretory activity. EMD 33290 in a single dose of 50 micrograms and 250 micrograms effectively protected human gastric mucosa against the injurious effects of aspirin and sodium taurocholate. It is therefore concluded that EMD 33290 has two distinct properties in the human stomach, viz. antisecretory and protective, which are independent of each other.

Adult↗
PubMed1982

[Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].

Ranitidine and oxmetidine are newly developed histamine H2-receptor antagonists without any antiandrogenic activity and probably without drug interactions. In numerous clinical trials ranitidine has been proven to be at least as effective as cimetidine in the short- and long-term treatment of peptic ulcer disease. Ranitidine was found to be remarkably safe. Its therapeutic use in man should not be associated with significant adverse reactions.

Biological Availability↗
PubMed1982

Microdetermination of glycerol using bacterial NADH-linked luciferase.

A bioluminescent assay for determination of glycerol using bacterial NADH-linked luciferase was developed and successfully applied to measurement of glycerol release from human fat cells. The procedure is based on enzymic conversion of glycerol to 3-phosphoglycerate, which is irreversible in the presence of arsenate, and subsequent determination of NADH formed in the glycerol-phosphate- and glyceraldehyde-3-phosphate dehydrogenase reactions respectively. Bioluminescent determination of glycerol is about 100 times more sensitive than conventional spectrophotometry, thus permitting more than 100 determinations to be carried out on needle biopsy specimens.

Adipose Tissue↗
PubMed1982

[Prevention of stress ulcer hemorrhage with H2-receptor blockade].

The prophylaxis of stress-induced gastrointestinal bleeding has gained particular clinical importance. The H2-receptor antagonist cimetidine as well as vigorous antacid treatment have been shown o be effective in preventing this complication. In six intensive care patients with an increased risk of gastrointestinal bleeding the new H2-receptor antagonist ranitidine in a dose of 0.125 mg/kg b.w./hr i.v. raised intragastric pH within two hours to values between 6.0 and 7.0. From these first data we may conclude that 200 mg i.v ranitidine daily may be at least as efficient as 1200 to 2000 mg i.v. daily cimetidine in inducing almost sustained anacidity. Its prophylactic use in high risk patients seems to be very promising.

Furans↗
PubMed1982

[Inhibition of acid secretion with substituted benzimidazole. A new principle in ulcer therapy?].

Substituted benzimidazoles inhibit gastric acid secretion stimulated by histamine, pentagastrin and vagal innervation. In contrast to anticholinergic agents and H2-receptor antagonists these compounds also block secretion induced by exogenous cyclic AMP suggesting a more peripheral site of action. Recent data show that these substances inhibit a H+/K+-ATPase which is localized at the secretory surface of the parietal cells and is generally regarded as the proton pump within the gastric mucosa. Because of the unique distribution of H+/K+-ATPase the inhibitory action of substituted benzimidazoles may offer a new therapeutic approach in hypersecretory states.

Adenosine Triphosphatases↗
PubMed1982

Adjuvant chemoimmunotherapy with LMF plus BCG in node-negative and node-positive breast cancer - intermediate report at 4 years.

A randomized surgical adjuvant trial in 242 evaluable patients with T1-3a, N0-1, and M0 breast cancer was initiated 4 years ago. The well-tolerated, oral combination chemotherapy with six cycles of Leukeran plus methotrexate plus fluorouracil (LMF) plus repeated BCG skin scarifications was used. After 4 years, the following results were seen: (1) significant increase of relapse-free (RFS) and also overall survival (S) in both pre- and postmenopausal node-negative patients versus surgical controls (RFS 91.1 vs. 701%, P = 0.003; S 96 vs. 88%, P = 0.03); (2) no significant increase of RFS or S in pre- and postmenopausal node-positive patients versus surgical controls (RFS 50.1 versus 44%, P = 0.49; S 70 versus 68 %, P = 0.9, respectively); (3) Patients receiving greater than 90% of the planned LMF dose showed significantly better survival after 4 years; and (4) Nonrandomized comparison with concurrent Swiss adjuvant studies with LMF alone indicate no beneficial or harmful effect of BCG skin scarifications in addition to the six-cycle LMF.

Breast Neoplasms↗
PubMed1982

[SKF 93479, a newly developed histamine H2-receptor antagonist. / Effect on gastric potential difference in the presence and absence of acetylsalicylic acid].

Acetylsalicylic acid (ASA) alters the gastric mucosal barrier as measured by the transmucosal potential difference (PD). The effect of the newly developed histamine H2-receptor antagonist 2-(2-(5-dimethylaminoethylfuran-2-ylmethylthio)ethylamino)-5-(6-methylpyrid-3-ylmethyl)pyrimid-4-one trihydrochloride (SKF 93479) on the ASA-induced drop in gastric PD was studied in 6 healthy volunteers. Mean basal PD was -38.5 to -39.5 mV. After 1000 mg of ASA PD decreased in 10-15 min to -25 mV. In subjects pretreated orally with 0.5 mg/kg SKF 93479, PD rose during 30-45 min to -53.5 mV. After ASA PD fell to -38.5 mV, but did not fall below normal.

Adult↗